N/A
Completed N=89
Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear
Source: ClinicalTrials.gov NCT02362724 ↗Enrolled (actual)
89
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Slit Lamp Findings for Epithelial Edema — 106; 58; 0; 0 Eyes
Summary
The purpose of the study is to compare the investigational contact lens to a marketed contact lens.
The study results were not used for design validation of investigational contact lens,
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Slit Lamp Findings for Epithelial Edema |
104; 56; 0; 0; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Epithelial Edema |
104; 56; 0; 0; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Stromal Edema |
104; 56; 0; 0; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Stromal Edema |
104; 56; 0; 0; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Corneal Infiltrates |
0; 0; 104; 56 | — |
| PRIMARY Slit Lamp Findings for Corneal Infiltrates |
0; 0; 104; 56 | — |
| PRIMARY Slit Lamp Findings for Corneal Vascularization |
101; 52; 3; 4; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Corneal Vascularization |
101; 52; 3; 4; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Limbal Hyperemia |
76; 44; 28; 12; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Limbal Hyperemia |
76; 44; 28; 12; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Bulbar Hyperemia |
70; 42; 33; 14; 1; 0 | — |
| PRIMARY Slit Lamp Findings for Bulbar Hyperemia |
70; 42; 33; 14; 1; 0 | — |
| PRIMARY Slit Lamp Findings for Palpebral Conjunctiva |
47; 20; 57; 36 | — |
| PRIMARY Slit Lamp Findings for Palpebral Conjunctiva |
47; 20; 57; 36 | — |
| PRIMARY Slit Lamp Findings for Other Findings |
101; 54; 3; 2; 0; 0 | — |
| PRIMARY Slit Lamp Findings for Other Findings |
101; 54; 3; 2; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Prior to being considered eligible to participate in this study, each subject MUST:
- Be at least 18 years of age as of the date of evaluation for the study.
- Have:
- Read the Informed Consent
- been given an explanation of the Informed Consent
- indicated understanding of the Informed Consent
- signed the Informed Consent document.
- Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
- Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
- Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
- Be in good general health, based on his/her knowledge.
- Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
- Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
- To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.
Exclusion Criteria
- Subjects may not be enrolled in this study if any of the following apply: The subject is currently or has:
- Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
- Poor personal hygiene.
- Any active participation in another clinical trial during this trial or within 30 days prior to this study.
- To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
- A member, relative or household member of the investigator or of the investigational office staff.
- Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
- Previous refractive surgery; or current or previous orthokeratology treatment.
- Is aphakic or psuedophakic.
- Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
- The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
- The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
- A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
- A history of papillary conjunctivitis that has interfered with contact lens wear.
- Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
- Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
- Pterygium
- Corneal scars within the visual axis
- Neovascularization or ghost vessels > 1.0 mm in from the limbus
- Giant papillary conjunctivitis (GPC) of > Grade 2
- Anterior uveitis or iritis
- Seborrheic eczema, seborrheic conjunctivitis or blepharitis
Data sourced from ClinicalTrials.gov (NCT02362724). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.